Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

1.

Predictors of loss to follow-up of tuberculosis cases under the DOTS programme in Namibia.

Kibuule D, Aiases P, Ruswa N, Rennie TW, Verbeeck RK, Godman B, Mubita M.

ERJ Open Res. 2020 Mar 16;6(1). pii: 00030-2019. doi: 10.1183/23120541.00030-2019. eCollection 2020 Jan.

2.

Second nationwide anti-tuberculosis drug resistance survey in Namibia.

Ruswa N, Mavhunga F, Roscoe JC, Beukes A, Shipiki E, van Gorkom J, Sawadogo S, Agolory S, Menzies H, Tiruneh D, Makumbi B, Bayer B, Zezai A, Campbell P, Alexander H, Kalisvaart N, Forster N.

Int J Tuberc Lung Dis. 2019 Jul 1;23(7):858-864. doi: 10.5588/ijtld.18.0526.

3.

Effectiveness of community-based DOTS strategy on tuberculosis treatment success rates in Namibia.

Kibuule D, Rennie TW, Ruswa N, Mavhunga F, Thomas A, Amutenya R, Law MR, G√ľnther G, Ette E, Godman B, Verbeeck RK.

Int J Tuberc Lung Dis. 2019 Apr 1;23(4):441-449. doi: 10.5588/ijtld.17.0785.

PMID:
31064623
4.

Renal function of MDR-TB patients treated with kanamycin regimens or concomitantly with antiretroviral agents.

Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Mengistu A, Mekonen TT, Leufkens HGM, Mantel-Teeuwisse AK.

Int J Tuberc Lung Dis. 2017 Dec 1;21(12):1245-1250. doi: 10.5588/ijtld.16.0953.

PMID:
29297444
5.

Adverse events and patients' perceived health-related quality of life at the end of multidrug-resistant tuberculosis treatment in Namibia.

Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HG, Mantel-Teeuwisse AK.

Patient Prefer Adherence. 2016 Nov 23;10:2369-2377. eCollection 2016.

6.

Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort.

Sagwa EL, Ruswa N, Mavhunga F, Rennie T, Leufkens HG, Mantel-Teeuwisse AK.

BMC Pharmacol Toxicol. 2015 Dec 10;16:36. doi: 10.1186/s40360-015-0036-7.

7.

Occurrence and clinical management of moderate-to-severe adverse events during drug-resistant tuberculosis treatment: a retrospective cohort study.

Sagwa EL, Mantel-Teeuwisse AK, Ruswa NC.

J Pharm Policy Pract. 2014 Oct 21;7(1):14. doi: 10.1186/2052-3211-7-14. eCollection 2014.

8.

Adverse events during treatment of drug-resistant tuberculosis: a comparison between patients with or without human immunodeficiency virus co-infection.

Sagwa E, Ruswa N, Musasa JP, Mantel-Teeuwisse AK.

Drug Saf. 2013 Nov;36(11):1087-96. doi: 10.1007/s40264-013-0091-1.

PMID:
23917883
9.

The burden of adverse events during treatment of drug-resistant tuberculosis in Namibia.

Sagwa E, Mantel-Teeuwisse AK, Ruswa N, Musasa JP, Pal S, Dhliwayo P, van Wyk B.

South Med Rev. 2012 Jul;5(1):6-13. Epub 2012 Jul 23.

Supplemental Content

Support Center